# Stimulant use and adverse outcomes in hospitalized people using opioids with infections

Amy W. Liu, MD<sup>1</sup>, Wei-Teng Yang, MD, MPH<sup>2</sup>, Sara N. Glick, PhD, MPH<sup>3</sup>, H. Nina Kim, MD, MSc<sup>3</sup>, Alison M. Beieler, PA-C, MPAS<sup>4</sup>, Kristine F. Lan, MS<sup>3</sup>, Shireesha Dhanireddy, MD<sup>3</sup>, Judith I. Tsui, MD, MPH<sup>1</sup>

<sup>1</sup>Division of General Internal Medicine, University of Washington, Seattle, WA, <sup>2</sup>Section of Addiction Medicine in Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, Portland, OR, <sup>3</sup>Division of Allergy and Infectious Diseases, University of Washington, <sup>4</sup>Infectious Disease & Travel Medicine Clinic, Harborview Medical Center, University of Washington

## Background

- Combined opioid and methamphetamine use is prevalent in King County, Washington, and associated with worse health outcomes (1,2).
- People who inject drugs (PWID) are at higher risk for severe infections, including bone and joint infections.
- In hospitalized patients who use opioids and have infections, there is limited data to show that coexisting stimulant use is associated with worse treatment outcomes (3).

## Methods

- **Study design**: Secondary analysis of a retrospective cohort of adults with recent self-reported injection drug use and clinically diagnosed bone and joint infection who were admitted to a university-affiliated urban teaching hospital in King County, Washington, between 2019-2021 (4).
- **Independent variables**: Combined opioid and stimulant use versus opioid use alone.
- **Outcome measures**: Infection treatment failure at 90 or 180 days, loss to follow-up at 180 days, and patient-directed discharges.
- Statistical analyses: T-tests and chi-squared tests were used to compare demographics between groups. Univariate logistic regression was used to assess associations between baseline co-existing stimulant use and outcomes.

#### Results

Table 1: Baseline demographics and clinical characteristics of hospitalized PWID with bone and joint infections using opioids (n=77).

Characteristic	Opioid Use Only (n=33)	Opioid and Stimulant Use (n=44)	p-value*
Partial Oral Treatment, n (%)	30 (91%)	36 (82%)	0.34
Age in years, mean (SD)	45 (11)	44 (12)	0.62
Female sex, n (%)	13 (39%)	17 (39%)	1.00
White, n (%)	28 (85%)	37 (84%)	0.81
Homeless, n (%)	14 (42%)	24 (55%)	0.36
MOUD in the hospital, n (%)	29 (88%)	34 (77%)	0.37

Table 2: Clinical outcomes of hospitalized PWID with bone and joint infections, by opioid use alone versus opioid plus stimulant use.

Outcome	Opioid Use Only (n=33)	Opioid and Stimulant Use (n=44)	p-value
Treatment failure, 90 days, n (%)	8 (24%)	16 (36%)	0.26
Treatment failure, 180 days, n (%)	9 (27%)	17 (39%)	0.30
Loss to follow-up, n (%)	10 (30%)	17 (39%)	0.45
Patient-directed discharge, n (%)	1 (3%)	11 (25%)	0.01

Table 3: Associations between stimulant use and adverse treatment outcomes among PWID with opioid use who are hospitalized for bone and joint infections.

Outcome	OR (95% CI)	p-value
Treatment failure, 90 days	1.79 (0.65-4.88)	0.26
Treatment failure, 180 days	1.68 (0.63-4.46)	0.30
Loss to follow-up	0.69 (0.26-1.80)	0.45
Patient-directed discharge	10.67 (1.30-87.46)	0.03

# Conclusions

- In this sample of PWID hospitalized for bone and joint infections with opioid use, the majority of patients (57%) used both opioids and stimulants.
- Combined opioid and stimulant use was associated with higher risk of patientdirected discharge.
- There was no statistically significant association between combined opioid and stimulant use and failure of treatment for infection or loss to follow-up. However, interpretation limited in context of small sample size.
- These findings suggest the need for interventions to address stimulant use for hospitalized patients with opioid use and severe infections to improve outcomes of infection treatment.

## References

- Glick, S. N., Klein, K. S., Tinsley, J., & Golden, M. R. (2021). Increasing Heroin-Methamphetamine (Goofball) Use and Related Morbidity Among Seattle Area People Who Inject Druss. Am J Addit, 30(2), 183-191. https://doi.org/10.1111/ajad.13115
- Lick, S. N., Burt, R., Kummer, K., Tinsley, J., Banta-Green, T., Hugas, Driv Z. Glick, S. N., Burt, R., Kummer, K., Tinsley, J., Banta-Green, C. J., & Golden, M. R. (2018). Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. Drug Alcohol Depend, 182, 86-92. https://doi.org/10.1016/j.drugalcdep.2017.10.011
- Levy, S., Bassler, J., Gagnon, K., Prados, M., Jeziorski, M., McCleskey, B., ... Eaton, E. (2022). Methamphetamines and Serious Injection Related Infections: Opioid Use Care Continuum and Opportunities to End Alabama's Drug Crisis. Open Forum Infectious Diseases. https://doi.org/10.1083/ofid/olac708
- Yang, W.-T., Dombrowski, J. C., Glick, S. N., Kim, H. N., Beieler, A. M., Lan, K. F., & Dhanireddy, S. (2023). Partial-oral antibiotic therapy for bone and joint infections in people with recent injection drug use. Open Forum Infectious Diseases. https://doi.org/10.1093/0fd/dad005

Funding/Disclosures: This work was supported by the NIH T32 grant number 5T32Al007044 (WTY). The authors do not declare financial conflicts of interest.